

519 Record 5077-76 27 JUL 2001

FORM PTO 1390 (REV 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER HO-P02246US0
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/890363 To be assigned		
INTERNATIONAL APPLICATION NO. PCT/GB00/00238	INTERNATIONAL FILING DATES 27 January 2000	PRIORITY DATE CLAIMED 27 January 1999 7 October 1999		
TITLE OF INVENTION FORMULATIONS COMPRISING ANTISENSE NUCLEOTIDES TO CONNEXINS				
APPLICANT(S) FOR DO/EO/US David Laurence Becker and Colin Richard Green				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p>				
Items 11 to 16 below concern document(s) or information included:				
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <ul style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. </p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: (a) PCT Request; (b) International Search Report; (c) International Preliminary Examination Report; and (d) Sequence Listing and Diskette</p>				

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER		
09/890363				
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)):				
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00				
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00				
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00				
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00				
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 860.00		
Surcharge of \$ 130.00 for furnishing the oath or declaration later than		\$ 130.00		
<input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	42 - 20 =	22	x 18.00	\$ 396.00
Independent claims	2 - 3 =	-0-	x -0-	\$ -0-
MULTIPLE DEPENDENT CLAIM(s) (if applicable)		x -0-	\$ -0-	
TOTAL OF ABOVE CALCULATIONS =		\$ 1,386.00		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.		\$		
SUBTOTAL =		\$ 1,386.00		
Processing fee of \$ for furnishing the English translation later than		\$		
<input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +		\$		
TOTAL NATIONAL FEE =		\$ 1,386.00		
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) (per property).		+ \$		
TOTAL FEES ENCLOSED =		\$ 1,386.00		
		Amount to be Refunded:	\$	
		Charged:	\$	
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.				
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 06-2375 in the amount of \$ 1,386.00 to cover the above fees. A duplicate copy of this sheet is enclosed.				
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. 06-2375. A duplicate copy of this sheet is enclosed.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO:		<i>Thomas D. Paul</i>		
Fulbright & Jaworski LLP Intellectual Property & Technology Section 1301 McKinney, Suite 5100 Houston, Texas 77010		THOMAS D. PAUL		
		NAME		
		32,714		
		REGISTRATION NUMBER		
July 27, 2001				

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO.:	To be assigned	§	DOCKET: P02246US0
FILING DATE:	July 27, 2001	§	
APPLICANT:	Becker <i>et al.</i>	§	EXAMINER: To be assigned
TITLE:	Formulations Comprising Antisense Nucleotides to Connexins	§	
		§	ART UNIT: To be assigned
		§	

Assistant Commissioner of Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING UNDER 37 C.F.R. §1.182-1.184


Dear Sir:

Applicants file the attached sequence listing and provide the enclosed computer readable disk for the national phase filing of the above-identified application for patent. The sequences are identical to those in the PCT application.

Applicants hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), are the same and that no new matter has been added.

Date: 7/27/01
Fulbright & Jaworski L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
Telephone (713) 651-3735

Respectfully submitted,



Thomas D. Paul
Reg. No. 45,579

09/890363

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	To be assigned	§	Docket No.: P02246US0
Filed:	July 27, 2001	§	
Applicant:	Becker <i>et al.</i>	§	Group Unit: Not yet assigned
Title:	Formulations Comprising Antisense Nucleotides to Connexins	§	Examiner: Not yet assigned
		§	
		§	

Box Patent Application
 Assistant Commissioner for Patents
 Washington D. C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

This is a Preliminary Amendment to accompany the U.S. National Phase filing of PCT/GB00/00238, international filing date January 27, 2000, with priority claims to January 27, 1999 (New Zealand 333928) and October 7, 1999 (New Zealand 500190). This Amendment substitutes the claims to be examined and presents the Sequence Listing. Applicants respectfully request that the Preliminary Amendment for the above-identified Application be entered as contained herein.

In the claims:

In this patent application, please consider under prosecution claims 1-42 wherein amended claims 1, 3, 4, 6, 9, 10-13, 15-17, 19, 20, 23, 24, 26, 27 and 30 are entered as contained herein. Please add claims 37-42. Claims 37-42 are added to comply with U.S. format and do not add new matter. Applicants respectfully request consideration of the following claims.

25055328.1

Express Mail Label No.
 EK102656891US (7/27/01)

1. A formulation for a therapeutic or a cosmetic treatment, which formulation comprises:
at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle.

3. A formulation according to claim 1, wherein the polynucleotide is an oligodeoxynucleotide.

4. A formulation according to claim 1 which contains polynucleotides to one connexin protein only.

6. A formulation according to claim 1 which contains polynucleotides to more than one connexin protein.

9. A formulation according to claim 5 in which the polynucleotide to connexin 43 is selected from the group consisting of:
GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and
GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

10. A formulation according to claim 5 in which the polynucleotide to connexin 26 is:
TCC TGA GCA ATA CCT AAC GAA CAA ATA.

11. A formulation according to claim 5 in which the polynucleotide to connexin 31.1 is:
CGT CCG AGC CCA GAA AGA TGA GGT C.

12. A formulation according to claim 5 in which the polynucleotide to connexin 32 is:
TTT CTT TTC TAT GTG CTG TTG GTG A.

13. A formulation according to claim 1 in which the pharmaceutically acceptable carrier or vehicle is, or includes, a gel.

15. A formulation according to claim 1 which further includes a surfactant or urea to assist with polynucleotide penetration into a cell.

16. A method of site-specific downregulation of connexin protein expression for a therapeutic or a cosmetic purpose which comprises administering a formulation as defined in claim 1 to a site on or within a patient at which said downregulation is required.

17. A method of reducing neuronal cell death which would otherwise result from a neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient which comprises the step of administering a formulation as defined in claim 1 to said site to downregulate expression of a connexin protein at and immediately adjacent said site.

19. A method according to claim 17 in which the formulation is administered in a sufficient amount to downregulate expression of said connexin protein for at least 24 hours post-administration.

20. A method of promoting wound healing in a patient which comprises the step of administering a formulation as defined in claim 1 to said wound to downregulate expression of a connexin protein at and immediately adjacent the site of said wound.

23. A method according to claim 20 in which the wound is the result of a surgery.

24. A method of reducing inflammation as part of treating a wound or a tissue subjected to a physical trauma which comprises the step of administering a formulation as defined in claim 1 to, or proximate to, said wound or tissue.

26. A method of decreasing scar formation in a patient who has suffered a wound which comprises the step of administering a formulation as defined in claim 1 to said wound to downregulate expression of a connexin protein at and immediately adjacent the site of said wound.

27. A method of skin rejuvenation or thickening for a cosmetic or a therapeutic purpose which comprises the step of administering, once or repeatedly, a formulation as defined in claim 1 to a skin surface.

30. A method according to claim 27 wherein said formulation is a cream.

37. A formulation according to claim 2, wherein the polynucleotide is an oligodeoxynucleotide.

38. A formulation according to claim 7 in which the polynucleotide to connexin 43 is selected from the group consisting of:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and
GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

39. A formulation according to claim 8 in which the polynucleotide to connexin 43 is selected from the group consisting of:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and
GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

40. A formulation according to claim 8 in which the polynucleotide to connexin 26 is:
TCC TGA GCA ATA CCT AAC GAA CAA ATA.

41. A formulation according to claim 8 in which the polynucleotide to connexin 31.1 is:

CGT CCG AGC CCA GAA AGA TGA GGT C.

42. A formulation according to claim 8 in which the polynucleotide to connexin 32 is:

TTT CTT TTC TAT GTG CTG TTG GTG A.

25055328.1

Express Mail Label No.
EK102656891US (7/27/01)

REMARKS

Please substitute and examine the above-presented claims for those pending in the PCT application. The above-presented claims represent re-written claims of the PCT application in U.S. format. These amendments do not narrow the scope of the claims within the meaning of *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd.*, 234 F3d 558, 586, 56 USPQ2d 1865, 1886 (Fed. Cir. 2000). No new matter has been added by these amendments.

Applicants have attached a marked version of the claims in this application. Additionally, Applicants have attached a clean copy of all pending claims in this application after amendments.

Applicants address fees in the Fee Transmittal filed herewith. However, if Applicants owe any additional fees now or at any time during the prosecution of this application, please charge the deposit account of Fulbright & Jaworski, L.L.P., account number 06-2375, from which the undersigned is authorized to withdraw.

Respectfully submitted,



Thomas D. Paul
Registration No. 32,714
Counsel for Applicants

Date: 7/27/01
Fulbright & Jaworski L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
Telephone: 713-651-5325
Telecopier: 713-651-5246

25055328.1

Express Mail Label No.
EK102656891US (7/27/01)

MARKED VERSION OF CLAIMS SHOWING AMENDMENTS

1. (Amended) A formulation for [use in] a therapeutic [and/] or a cosmetic treatment, which formulation comprises:

at least one anti-sense polynucleotide to a connexin protein[;] together with a pharmaceutically acceptable carrier or vehicle.

3. (Amended) A formulation according to claim 1 [or 2], wherein the polynucleotide is an oligodeoxynucleotide.

4. (Amended) A formulation according to [any preceding] claim 1 which contains polynucleotides to one connexin protein only.

6. (Amended) A formulation according to [any of] claim[s] 1 [to 3] which contains polynucleotides to more than one connexin protein.

9. (Amended) A formulation according to claim 5 [, claim 7 or claim 8] in which the polynucleotide to connexin 43 is selected from the group consisting of:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and

GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

10. (Amended) A formulation according to claim 5 [or claim 8] in which the polynucleotide to connexin 26 is:

TCC TGA GCA ATA CCT AAC GAA CAA ATA.

11. (Amended) A formulation according to claim 5 [or claim 8] in which the polynucleotide to connexin 31.1 is:

CGT CCG AGC CCA GAA AGA TGA GGT C.

12. (Amended) A formulation according to claim 5 [or claim 8] in which the polynucleotide to connexin 32 is:

TTT CTT TTC TAT GTG CTG TTG GTG A.

13. (Amended) A formulation according to [any preceding] claim 1 in which the pharmaceutically acceptable carrier or vehicle is, or includes, a gel.

15. (Amended) A formulation according to [any preceding] claim 1 which further includes a surfactant or urea to assist with polynucleotide penetration into a cell[s].

16. (Amended) A method of site-specific downregulation of connexin protein expression for a therapeutic [and/] or a cosmetic purpose which comprises administering a formulation as defined in [any one of] claim[s] 1 [to 15] to a site on or within a patient at which said downregulation is required.

17. (Amended) A method of reducing neuronal cell death which would otherwise result from a neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient which comprises the step of administering a formulation as defined in [any one of] claim[s] 1 [to 15] to said site to downregulate expression of a connexin protein[(s)] at and immediately adjacent said site.

19. (Amended) A method according to claim 17 in which the formulation is administered in a sufficient amount to downregulate expression of said connexin protein[(s)] for at least 24 hours post-administration.

20. (Amended) A method of promoting wound healing in a patient which comprises the step of administering a formulation as defined in [any of] claim[s] 1 [to 15] to said wound to downregulate expression of a connexin protein[(s)] at and immediately adjacent the site of said wound.

23. (Amended) A method according to claim 20 in which the wound is the result of a surgery.

24. (Amended) A method of reducing inflammation as part of treating a wound [and/] or a tissue subjected to a physical trauma which comprises the step of administering a formulation as defined in [any one of] claim[s] 1 [to 15] to, or proximate to, said wound or tissue.

26. (Amended) A method of decreasing scar formation in a patient who has suffered a wound which comprises the step of administering a formulation as defined in [any one of] claim[s] 1 [to 15] to said wound to downregulate expression of a connexin protein[(s)] at and immediately adjacent the site of said wound.

27. (Amended) A method of skin rejuvenation or thickening for a cosmetic or a therapeutic purpose which comprises the step of administering, once or repeatedly, a formulation as defined in [any one of] claim[s] 1 [to 15] to a [the] skin surface.

30. (Amended) A method according to [any one of] claim[s] 27 [to 29] wherein said formulation is a cream.

CLEAN COPY OF ALL PENDING CLAIMS AS OF JULY 27, 2001

1. (Amended) A formulation for a therapeutic or a cosmetic treatment, which formulation comprises:

at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle.

2. A formulation according to claim 1, suitable for topical administration.
3. (Amended) A formulation according to claim 1, wherein the polynucleotide is an oligodeoxynucleotide.
4. (Amended) A formulation according to claim 1 which contains polynucleotides to one connexin protein only.
5. A formulation according to claim 4 wherein said connexin protein is connexin 43, connexin 26, connexin 31.1, connexin 32 or connexin 36.
6. (Amended) A formulation according to claim 1 which contains polynucleotides to more than one connexin protein.
7. A formulation according to claim 6 in which one of the connexin proteins to which polynucleotides are directed is connexin 43.
8. A formulation according to claim 6 which includes polynucleotides directed to at least two of connexin 26, connexin 31.1, connexin 32, connexin 36 and connexin 43.

9. (Amended) A formulation according to claim 5 in which the polynucleotide to connexin 43 is selected from the group consisting of:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and
GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

10. (Amended) A formulation according to claim 5 in which the polynucleotide to connexin 26 is:

TCC TGA GCA ATA CCT AAC GAA CAA ATA.

11. (Amended) A formulation according to claim 5 in which the polynucleotide to connexin 31.1 is:

CGT CCG AGC CCA GAA AGA TGA GGT C.

12. (Amended) A formulation according to claim 5 in which the polynucleotide to connexin 32 is:

TTT CTT TTC TAT GTG CTG TTG GTG A.

13. (Amended) A formulation according to claim 1 in which the pharmaceutically acceptable carrier or vehicle is, or includes, a gel.

14. A formulation according to claim 13 in which the gel is a nonionic polyoxyethylene-polyoxypropylene copolymer gel.

15. (Amended) A formulation according to claim 1 which further includes a surfactant or urea to assist with polynucleotide penetration into a cell.

16. (Amended) A method of site-specific downregulation of connexin protein expression for a therapeutic or a cosmetic purpose which comprises administering a formulation as defined in claim 1 to a site on or within a patient at which said downregulation is required.

17. (Amended) A method of reducing neuronal cell death which would otherwise result from a neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient which comprises the step of administering a formulation as defined in claim 1 to said site to downregulate expression of a connexin protein at and immediately adjacent said site.

18. A method according to claim 17 in which the formulation is administered to reduce neuronal loss due to physical trauma to the brain, spinal cord or optic nerve.

19. (Amended) A method according to claim 17 in which the formulation is administered in a sufficient amount to downregulate expression of said connexin protein for at least 24 hours post-administration.

20. (Amended) A method of promoting wound healing in a patient which comprises the step of administering a formulation as defined in claim 1 to said wound to downregulate expression of a connexin protein at and immediately adjacent the site of said wound.

21. A method according to claim 20 in which the wound is the result of trauma.

22. A method according to claim 21 in which the trauma is a burn.

23. (Amended) A method according to claim 20 in which the wound is the result of a surgery.

24. (Amended) A method of reducing inflammation as part of treating a wound or a tissue subjected to a physical trauma which comprises the step of administering a formulation as defined in claim 1 to, or proximate to, said wound or tissue.

25. A method according to claim 24 in which the formulation is administered to reduce inflammation due to physical trauma to the brain, spinal cord or optic nerve.

26. (Amended) A method of decreasing scar formation in a patient who has suffered a wound which comprises the step of administering a formulation as defined in claim 1 to said wound to downregulate expression of a connexin protein at and immediately adjacent the site of said wound.

27. (Amended) A method of skin rejuvenation or thickening for a cosmetic or a therapeutic purpose which comprises the step of administering, once or repeatedly, a formulation as defined in claim 1 to a skin surface.

28. A method according to claim 27 wherein said formulation includes polynucleotide directed to connexin 43 and is administered to regulate epithelial basal cell division and growth.

29. A method according to claim 27 wherein said formulation includes polynucleotide directed to connexin 31.1 and is administered to regulate outer layer keratinisation.

30. (Amended) A method according to claim 27 wherein said formulation is a cream.

31. The use of at least one anti-sense polynucleotide to a connexin protein in the manufacture of a medicament for downregulating expression of said connexin protein for a therapeutic or cosmetic purpose.

32. The use of claim 31 wherein said medicament is for reducing neuronal cell death which would otherwise result from a neuronal insult.

33. The use of claim 31 wherein said medicament is for promoting wound healing.

34. The use of claim 31 wherein said medicament is for reducing inflammation.

35. The use of claim 31 wherein said medicament is for decreasing scar formation.

36. The use of claim 31 wherein said medicament is for skin rejuvenation for a cosmetic or therapeutic purpose.

37. A formulation according to claim 2, wherein the polynucleotide is an oligodeoxynucleotide.

38. A formulation according to claim 7 in which the polynucleotide to connexin 43 is selected from the group consisting of:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and

GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

39. A formulation according to claim 8 in which the polynucleotide to connexin 43 is selected from the group consisting of:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and

GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

40. A formulation according to claim 8 in which the polynucleotide to connexin 26 is:

TCC TGA GCA ATA CCT AAC GAA CAA ATA.

41. A formulation according to claim 8 in which the polynucleotide to connexin 31.1 is:

CGT CCG AGC CCA GAA AGA TGA GGT C.

42. A formulation according to claim 8 in which the polynucleotide to connexin 32 is:

TTT CTT TTC TAT GTG CTG TTG GTG A.

FORMULATIONS COMPRISING ANTISENSE NUCLEOTIDES TO CONNEXINS

This invention relates to formulations for use in therapeutic and/or cosmetic treatments, particularly those in which a localised disruption in direct cell-cell communication is desirable.

BACKGROUND

Gap junctions are cell membrane structures which facilitate direct cell-cell communication. A gap junction channel is formed of two hemichannels 10 (connexons), each composed of six connexin subunits. These connexins are a family of proteins, commonly named according to their molecular weight or classified on a phylogenetic basis ie. into an α class and a β class.

An ability to control connexin expression (and in particular to downregulate it) would therefore provide an opportunity to modulate cell-cell communication 15 within a patient for therapeutic and/or remedial purposes. However, as a number of connexin proteins are expressed widely throughout the body, a general downregulatory effect is undesirable in inducing a therapeutic effect at a specific site.

Anti-sense oligodeoxynucleotides (ODN's) have considerable potential as 20 agents for the manipulation of specific gene expression (reviewed: Stein *et al.*, 1992; Wagner 1994). However, there remain difficulties which need to be overcome. These include the short half life of such ODN's (unmodified phosphodiester oligomers typically have an intracellular half life of only 20 minutes owing to intracellular nuclease degradation (Wagner 1994)) and their 25 delivery consistently and reliably to target tissues.

It was with the intent of at least partially overcoming these difficulties that the applicants devised the present invention.

-2-

SUMMARY OF THE INVENTION

Accordingly, in a first aspect, the invention provides a formulation for use in therapeutic and/or cosmetic treatment, which formulation comprises:

at least one anti-sense polynucleotide to a connexin protein; together with
5 a pharmaceutically acceptable carrier or vehicle.

In one preferred form, the formulation contains polynucleotides to one connexin protein only. Most preferably, this connexin protein is connexin 43.

Many aspects of the invention are described with reference to
oligodeoxynucleotides. However it is understood that other suitable
10 polynucleotides (such as RNA polynucleotides) may be used in these aspects.

Alternatively, the formulation contains oligodeoxynucleotides to more than one connexin protein. Preferably, one of the connexin proteins to which oligodeoxynucleotides are directed is connexin 43. Other connexin proteins to which oligodeoxynucleotides are directed include connexin 26, connexin 31.1 and
15 connexin 32.

Conveniently, the oligodeoxynucleotide to connexin 43 is selected from:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and
20 GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT

Most conveniently, the oligodeoxynucleotide to connexin 43 is:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC.
25 Conveniently, the oligodeoxynucleotide to connexin 26 is:

TCC TGA GCA ATA CCT AAC GAA CAA ATA.

30 Conveniently, the oligodeoxynucleotide to connexin 31.1 is:

-3-

CGT CCG AGC CCA GAA AGA TGA GGT C.

Conveniently, the oligodeoxynucleotide to connexin 32 is:

5 TTT CTT TTC TAT GTG CTG TTG GTG A.

The anti-sense polynucleotides may be formulated for parenteral, intramuscular, intracerebral, intravenous, subcutaneous or transdermal administration. The antisense polynucleotides are preferably administered topically 10 (at the site to be treated). Suitably the antisense polynucleotides are combined with a pharmaceutically acceptable carrier, vehicle or diluent to provide a pharmaceutical composition.

Suitable pharmaceutically acceptable carriers or vehicles include any of those commonly used for topical administration. The topical formulation may be 15 in the form of a cream, ointment, gel, emulsion, lotion or paint. The formulation of the invention may also be presented in the form of an impregnated dressing.

Suitable carrier materials include any carrier or vehicle commonly used as a base for creams, lotions, gels, emulsions, lotions or paints for topical 20 administration. Examples include emulsifying agents, inert carriers including hydrocarbon bases, emulsifying bases, non-toxic solvents or water-soluble bases. Particularly suitable examples include lanolin, hard paraffin, liquid paraffin, soft yellow paraffin or soft white paraffin, white beeswax, yellow beeswax, cetostearyl alcohol, cetyl alcohol, dimethicones, emulsifying waxes, isopropyl myristate, microcrystalline wax, oleyl alcohol and stearyl alcohol.

25 Preferably, the pharmaceutically acceptable carrier or vehicle is a gel, suitably a nonionic polyoxyethylene-polyoxypropylene copolymer gel, for example, a Pluronic gel, preferably Pluronic F-127 (BASF Corp.). This gel is particularly preferred as it is a liquid at low temperatures but rapidly sets at physiological temperatures, which confines the release of the ODN component to 30 the site of application or immediately adjacent that site.

An auxiliary agent such as casein, gelatin, albumin, glue, sodium alginate, carboxymethylcellulose, methylcellulose, hydroxyethylcellulose or polyvinyl alcohol may also be included in the formulation of the invention.

5 The pharmaceutical composition may be formulated to provide sustained release of the antisense polynucleotide.

Conveniently, the formulation further includes a surfactant to assist with oligodeoxynucleotide cell penetration or the formulation may contain any suitable loading agent. Any suitable non-toxic surfactant may be included, such as DMSO. Alternatively a transdermal penetration agent such as urea may be included.

10 In a further aspect, the invention provides a method of site-specific downregulation of connexin protein expression for a therapeutic and/or cosmetic purpose which comprises administering a formulation as defined above to a site on or within a patient at which said downregulation is required.

15 In still a further aspect, the invention provides a method of reducing neuronal cell death which would otherwise result from a neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient which comprises the step of administering a formulation as defined above to said site to downregulate expression of connexin protein(s) at and immediately adjacent said site.

20 Preferably, the formulation is administered to reduce neuronal loss due to physical trauma to the brain, spinal cord or optic nerve.

Conveniently, the formulation is administered in a sufficient amount to downregulate expression of said connexin protein(s) for at least 24 hours post-administration.

25 In yet a further aspect, the invention provides a method of promoting wound healing in a patient which comprises the step of administering a formulation as defined above to said wound to downregulate expression of connexin protein(s) at and immediately adjacent the site of said wound.

Usually, the wound will be the result of trauma, including burns. It may however be the result of surgery.

30 In yet a further aspect, the invention provides a method of reducing

inflammation as part of treating a wound and/or tissue subjected to physical trauma which comprises the step of administering a formulation as defined above to or proximate to said wound or tissue.

Preferably, said wound is a burn.

5 Alternatively, said wound is the result of physical trauma to tissue, including neuronal tissue such as the brain, spinal cord or optic nerve.

In yet a further aspect, the invention provides a method of decreasing scar formation in a patient who has suffered a wound which comprises the step of administering a formulation as defined above to said wound to downregulate 10 expression of connexin protein(s) at and immediately adjacent the site of said wound.

Again, the wound may be the result of trauma or surgery, with the formulation being applied to the wound immediately prior to surgical repair and/or closure thereof.

15 In yet a further aspect, the invention provides a method of skin rejuvenation or thickening for a cosmetic or therapeutic purpose which comprises the step of administering, once or repeatedly, a formulation as defined above to the skin surface.

Conveniently, said formulation includes oligodeoxynucleotides directed to connexin 26 or connexin 43 and is administered to regulate epithelial basal cell division and growth.

20 In another embodiment, said formulation includes oligodeoxynucleotides directed to connexin 31.1 and is administered to regulate outer layer keratinisation.

Preferably, the formulation is a cream or gel.

DESCRIPTION OF THE DRAWINGS

25 Figures 1 to 5 show sections of rat brain lesions treated with Pluronic gel containing antisense oligodeoxynucleotides specific to connexin 43, or for control lesions, Pluronic gel alone. In all cases lesions were sectioned serially in a coronal plane and the mid point sections used for analysis. Each image (except Figure 5) shows 4 mm by 5.33 mm of tissue. Figure 5 is approximately 1.2 mm by 2 mm.

30 Figure 1: Figures 1A and 1C show two side of a control lesion 24 hours after

-6-

lesioning. The lesion has been treated with Pluronic gel alone. The sections have been Nissl stained (blue nuclei) and antibody labelled with the neuronal marker Neuronal-N (brown cells). Figures 1B and 1D show grey scale images of 1A and 1C respectively with the outline of the lesion marked. Note the large size of the lesion
5 and the irregular spreading edges. The lesion has spread downwards toward the corpus callosum (dashed line) within just 24 hours of lesioning.

Figure 2: A control lesion 24 hours after wounding. Figure 2A shows Nissl staining (blue nuclei) and Neuronal-N labelling of viable neurons. Figure 2B is a grey scale equivalent with the lesion edge marked and the top of the corpus callosum marked (dashed line). The original needle tract is clear but neuronal death has occurred well back from the lesion edge as indicated by the Neuronal-N labelling. The edges of the lesion are irregular and the lesion, within just 24 hours, has spread right down into the corpus callosum.

Figure 3: Figures 3A and 3B are colour and grey scale images of a connexin
15 43 antisense treated lesion, 48 hours after lesioning. The lesion outline has been marked on Figure 3B to show the extent of the lesion and the top of the corpus callosum marked (dashed line). Figure 3A has been stained for Nissl (blue nuclei) and Neuronal-N (pink cells). Note how compact the lesion is, even after 48 hours, compared with control lesions (Figures 1 and 2). While there is some spread to the
20 right hand side, the left side of the lesion essentially follows the original needle tract with little sign of spreading. The left side of the lesion is very straight and it has not spread down to the corpus callosum.

Figure 4: Figures 4A and 4B show another connexin 43 antisense treated lesion 48 hours after wounding. The labelling is the same as in Figure 3 with the
25 lesion outlined on the grey scale image (Figure 4B). Even after 48 hours this lesion is extremely compact with slight spreading only to the left (medial side). Note how straight the right hand side of the lesion is with viable neurons right up to the edge of the needle tract (and indeed surviving within the lesioned area). The lesion is well above the corpus callosum (dashed line) indicating virtually no downward spread.

30 Figure 5: A higher magnification view showing the edge of a connexin 43

antisense treated lesion. The edge of the lesion has been marked showing viable neurons (Neuronal-N labelled) right up to the edge of the wounding needle tract even 48 hours after lesioning.

Figure 6: GFAP (red) and connexin43 (green) immunohistochemical labelling of a connexin43 specific antisense treated lesion, 24 hours after lesioning. The image is taken at the lateral edge of the lesion at a point half way down the depth of the lesion. Activated astrocyte levels are elevated compared with controls (Figure 7) and connexin 43 levels are markedly reduced. The connexin labelling remaining is generally associated with blood vessels (arrows).

Figure 7: GFAP (red) and connexin43 (green) immunohistochemical labelling of a control lesion, 24 hours after lesioning. The image is from the medial edge of the lesion and shows GFAP levels slightly elevated over unlesioned cortex. Note the extensive connexin 43 labelling, often co-localised with the GFAP astrocytic marker (arrows).

Figure 8 shows a comparison of lesion cross sectional lower half areas 24 hours (circles) and 48 hours (diamonds) after lesioning. The analysis was carried out on a mid section of serially sectioned lesion cut on the coronal plane. Lesions were assessed using Neuronal-N antibody labelling to delineate viable neurons. DB1 treated lesions (green markers) have been treated with antisense oligodeoxynucleotides specific to connexin 43. The gel only lesion group (red markers) also includes empty lesions while the HB3 group (purple markers) are treated with gel containing random sequence control oligodeoxynucleotides. Note that while connexin 43 antisense treated lesions can be large (presumably where the antisense has not been well delivered), the smallest lesions are all connexin 43 antisense treated. Lesions were made to a depth of 2 mm and analysis covers 1 mm and below so as to exclude the outer edge where the antisense did not sit.

Figure 9: Lesions in rat spinal cord 24 hours after treatment with connexin 43 sense and antisense ODN's. The sense lesions were no different from untreated controls whereas the antisense treated lesions were smaller and with reduced inflammation.

-8-

Figure 10: Lesions in neonatal mouse fore paws 24 hours after treatment with connexin 43 sense ODNs (left paw) or antisense ODNs (right paw). Note the reduction in inflammation and increased rate of healing on the antisense treated paw.

Figure 11: Sections through the centre of the 24 hour wounds shown in 5 Figure 10. The sections have been stained with toluidine blue to reveal neutrophils. There are significantly less neutrophils in the antisense treated wound which was also less inflamed.

Figure 12: Pairs of rat paw lesions five days after lesioning that have been 10 treated with connexin 43 specific antisense ODNs or sense control ODNs. Antisense treated lesions are healing quicker and show less signs of scarring.

Figure 13: Pairs of rat paw lesions made at the neonate stage, and viewed here 8 days after lesioning. Lesions were treated with connexin 43 specific antisense or control sense ODN. Hair has grown and it is clear that antisense treatment has resulted in smaller scars and less hair loss. The site of the lesion remains prominent 15 in the sense treated control but is difficult to detect in the antisense treated limb.

DESCRIPTION OF THE INVENTION

As broadly defined above, the focus of the invention is on site-specific 20 downregulation of connexin expression. This will have the effect of reducing direct cell-cell communication at the site at which connexin expression is downregulated, which gives rise to numerous therapeutic/cosmetic applications as described below.

The downregulation of connexin expression is based generally upon the anti-sense approach using antisense polynucleotides (such as DNA or RNA 25 polynucleotides), and more particularly upon the use of antisense oligodeoxynucleotides (ODN). These polynucleotides (eg. ODN) target the connexin protein(s) to be downregulated. Typically the polynucleotides are single stranded, but may be double stranded.

The antisense polynucleotide may inhibit transcription and/or translation of 30 the connexin. Preferably the polynucleotide is a specific inhibitor of transcription and/or translation from the connexin gene, and does not inhibit transcription and/or

translation from other genes. The product may bind to the connexin gene or mRNA either (i) 5' to the coding sequence, and/or (ii) to the coding sequence, and/or (iii) 3' to the coding sequence.

Generally the antisense polynucleotide will cause the expression of 5 connexin mRNA and/or protein in a cell to be reduced.

The antisense polynucleotide is generally antisense to the connexin mRNA. Such a polynucleotide may be capable of hybridising to the connexin mRNA and may thus inhibit the expression of connexin by interfering with one or more aspects of connexin mRNA metabolism including transcription, mRNA processing, mRNA 10 transport from the nucleus, translation or mRNA degradation. The antisense polynucleotide typically hybridises to the connexin mRNA to form a duplex which can cause direct inhibition of translation and/or destabilisation of the mRNA. Such a duplex may be susceptible to degradation by nucleases.

The antisense polynucleotide may hybridize to all or part of the connexin 15 mRNA. Typically the antisense polynucleotide hybridizes to the ribosome binding region or the coding region of the connexin mRNA. The polynucleotide may be complementary to all of or a region of the connexin mRNA. For example, the polynucleotide may be the exact complement of all or a part of connexin mRNA. However, absolute complementarity is not required and polynucleotides which have 20 sufficient complementarity to form a duplex having a melting temperature of greater than 20°C, 30°C or 40°C under physiological conditions are particularly suitable for use in the present invention.

Thus the polynucleotide is typically a homologue of the mRNA. The polynucleotide may be a polynucleotide which hybridises to the connexin mRNA 25 under conditions of medium to high stringency such as 0.03M sodium chloride and 0.03M sodium citrate at from about 50 to about 60 degrees centigrade.

The polynucleotide will typically be from 6 to 40 nucleotides in length. Preferably it will be from 12 to 20 nucleotides in length. The polynucleotides may be at least 40, for example at least 60 or at least 80, nucleotides in length and up to 30 100, 200, 300, 400, 500, 1000, 2000 or 3000 or more nucleotides in length.

-10-

The connexin protein or proteins targeted by the ODN will be dependent upon the site at which downregulation is to be effected. This reflects the non-uniform make-up of gap junction(s) at different sites throughout the body in terms of connexin sub-unit composition. The connexin may be any connexin that naturally occurs in a human or animal. The connexin gene (including coding sequence) generally has homologue with any of the specific connexins mentioned herein, such as homology with the connexin 43 coding sequence shown in Table 1. The connexin is typically an α or β connexin. Preferably the connexin is expressed in the skin or nervous tissue (including brain cells).

Some connexin proteins are however more ubiquitous than others in terms of distribution in tissue. One of the most widespread is connexin 43. ODN's targeted to connexin 43 are therefore particularly suitable for use in the present invention.

It is also contemplated that ODN's targeted at separate connexin proteins be used in combination (for example 1, 2, 3, 4 or more different connexins may be targeted). For example, ODN's targeted to connexin 43, and one or more other members of the connexin family (such as connexin 26, 31.1, 32, 36, 40 and 45) can be used in combination.

Individual antisense polynucleotides may be specific to a particular connexin, or may target 1, 2, 3 or more different connexins. Specific polynucleotides will generally target sequences in the connexin gene or mRNA which are not conserved between connexins, whereas non-specific polynucleotides will target conserved sequences.

The ODN's for use in the invention will generally be unmodified phosphodiester oligomers. They will vary in length but with a 30 mer ODN being particularly suitable.

The antisense polynucleotides may be chemically modified. This may enhance their resistance to nucleases and may enhance their ability to enter cells. For example, phosphorothioate oligonucleotides may be used. Other deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates,

-11-

N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methylribonucleotide methylphosphonates.

Alternatively mixed backbone oligonucleotides (MBOs) may be used.

MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately

5 placed segments of modified oligodeoxy- or oligoribonucleotides. MBOs have segments of phosphorothioate linkages and other segments of other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'-O-alkyoligonucleotides.

The precise sequence of the antisense polynucleotide used in the invention
10 will depend upon the target connexin protein. For connexin 43, the applicant's have found ODN's having the following sequences to be particularly suitable:

GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and

15 GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT

ODN's directed to other connexin proteins can be selected in terms of their nucleotide sequence by any convenient, and conventional, approach. For example, the computer programmes MacVector and OligoTech (from Oligos etc. Eugene, 20 Oregon, USA) can be used. For example, ODN's for connexins 26, 31.1 and 32 have the following sequences:

5' TCC TGA GCA ATA CCT AAC GAA CAA ATA (connexin 26)

5' CGT CCG AGC CCA GAA AGA TGA GGT C (connexin 31.1)

25 5' TTT CTT TTC TAT GTG CTG TTG GTG A (connexin 32)

Once selected, the ODN's can be synthesised using a DNA synthesiser.

For use in the invention, the ODN(s) require site-specific delivery. They also require delivery over an extended period of time. While clearly the delivery 30 period will be dependent upon both the site at which the downregulation is to be

-12-

induced and the therapeutic effect which is desired, continuous delivery for 24 hours or longer will often be required.

In accordance with the present invention, this is achieved by inclusion of the ODN(s) in a formulation together with a pharmaceutically acceptable carrier or 5 vehicle, particularly in the form of a formulation for topical administration.

Once prepared, the formulations of the invention have utility in any therapeutic/cosmetic approach where a transient and site-specific interruption in cell-cell communication is desirable. These include in treating neuronal damage in the brain, spinal cord or optic nerve (where the damage is to be localised as much as 10 possible), in the promotion of wound healing and in reducing scar formation following, for example, cosmetic surgery or burns.

In particular, topical formulations such as creams can be employed to regulate epithelial basal cell division and growth (using ODN's targeted to connexin 43) and outer layer keratinisation (using ODN's targeted to connexin 31.1).

15 The antisense polynucleotides (including the ODN) may be present in a substantially isolated form. It will be understood that the product may be mixed with carriers or diluents which will not interfere with the intended purpose of the product and still be regarded as substantially isolated. A product of the invention may also be in a substantially purified form, in which case it will generally comprise 90%, e.g. at 20 least 95%, 98% or 99% of the polynucleotide or dry mass of the preparation.

Administration

The antisense polynucleotides (including ODN's) of the invention (typically in the form of the formulation discussed herein) may thus be administered to a 25 human or animal in need of treatment, such as a human or animal with any of the diseases or conditions mentioned herein. The condition of the human or animal can thus be improved. The polynucleotide and formulation may thus be used in the treatment of the human or animal body by therapy. They may be used in the manufacture of a medicament to treat any of the conditions mentioned herein.

30 The antisense polynucleotides may be administered by typically (at the site

-13-

to be treated). Preferably the antisense polynucleotides are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for 5 parenteral, intramuscular, intracerebral, intravenous, subcutaneous, or transdermal administration.

The dose at which an antisense polynucleotide is administered to a patient will depend upon a variety of factors such as the age, weight and general condition of the patient, the condition that is being treated, and the particular antisense 10 polynucleotide that is being administered. A suitable dose may however be from 0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight.

Uptake of nucleic acids by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. The formulation which is administered may contain such agents. Example of these 15 agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM).

The routes of administration and dosages described above are intended only as a guide since a skilled physician will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

20

Homologues

Homology and homologues are discussed herein (eg. the polynucleotides may be a homologue of sequence in connexin mRNA). Such polynucleotides typically have at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% 25 homology with the relevant sequence, for example over a region of at least 15, 20, 40, 100 more contiguous nucleotides (of the homologous sequence).

Homology may be calculated based on any method in the art. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux *et al* (1984) *Nucleic 30 Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to

calculate homology or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F *et al* (1990) *J Mol Biol* 215:403-10.

Software for performing BLAST analyses is publicly available through the

5 National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold

10 (Altschul *et al*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved
15 value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm
25 is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

-15-

The homologous sequence typically differs from the relevant sequence by at least (or by no more than) 2, 5, 10, 15, 20 more mutations (which may be substitutions, deletions or insertions). These mutations may be measured across any of the regions mentioned above in relation to calculating homology.

5 The homologous sequence typically hybridises selectively to the original sequence at a level significantly above background. Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C). However, such hybridisation may be carried out under any suitable conditions known

10 in the art (see Sambrook *et al* (1989), Molecular Cloning: A Laboratory Manual). For example, if high stringency is required, suitable conditions include 0.2 x SSC at 60°C. If lower stringency is required, suitable conditions include 2 x SSC at 60°C.

15 Various aspects of the invention will now be described with reference to the following experimental section which will be understood to be provided by way of illustration only and not to constitute a limitation on the scope of the invention.

EXPERIMENTAL

EXPERIMENT 1

5 MATERIALS AND METHODS

Antisense application

30% Pluronic F-127 gel (BASF Corp) in phosphate buffered saline (molecular grade water) was used to deliver unmodified a1 connexin (connexin 43) 10 specific anti-sense ODN's to the developing chick embryo (Simons, *et al.*, 1992). Chick embryos were incubated at 38°C and staged according to Hamilton and Hamburger stages. Eggs were windowed and the viteline and amniotic membranes over the area to be treated were opened using fine forceps. After anti-sense 15 application eggs were sealed with tape and replaced in the incubator for 48 hours at which time most experiments were analysed, the exception being for the time course analysis of a1 connexin "knockdown" and recovery.

Pluronic gel is liquid at low temperatures, 0-4°C, but sets when dropped onto the embryo at physiological temperature, remaining in place for at least 12 hours. The gel has the additional advantage of being a mild surfactant and this, used 20 either alone or in conjunction with DMSO, appeared to markedly expedite ODN penetration into cells (Wagner, 1994). Addition of an FITC tag to DB1 ODN, viewed using confocal laser scanning microscopy, demonstrated intracellular penetration of the probes. Sequences of deoxyoligonucleotides used are shown in Table 1.

Table 1: The Effect on Limb Development of ODN Application Between Stages 8 & 14 of Chick Embryo Development

5 Antisense oligodeoxynucleotides to Connexin 43
DB1 GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC
CG1 GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT
Control oligodeoxynucleotides
DB1(sense) GAC AGA AAC AAT TCC TCC TGC CGC AAT TAC
10 DB1(chick) GTA GTT ACG ACA GGA GGA ATT GTT CTC GTC
CV3(random) TCG AAC TGT CAA GAC TGC TAT GGC GAT CAT
Gel only

All ODN's were applied at 0.5-1.0 mM final concentration following dose
15 dependent analysis during preliminary experiments covering a range of
concentrations from 0.05 mM to 50 mM. General toxicity effects only became
apparent with ODN concentrations greater than 10 mM. ODN gel mixtures were
prepared from concentrated stock solutions stored at -80°C.

20 **Anti-sense sequences**

DB1 is a mouse anti-sense sequence, complementary to bases 1094 - 1123
of the a1 connexin gene. It has four mismatches with chick a1 connexin sequence.
CG1 is complementary to chick a1 connexin bases 720-749. Efficacy of this probe
was improved with 1% Dimethylsulphoxide (DMSO) added to the gel. DMSO had
25 no added effect on other anti-sense ODN or control results.

Control sequences

DB1(Chick) is the chick a1 connexin equivalent of DB1 matching chick a1
connexin bases 954-983. Analysis however, indicates a high probability of forming
30 stem loop structures ($G = -7.0$ kcal/mol, Loop $T_m = 92^\circ$) and homodimerisation (T_m
 $= 1.5^\circ$) and therefore acts as a control sequence. It has been reported that some sense
oligonucleotides can form stable DNA triplets (Neckers *et al.*, 1993) inhibiting
transcription. However, this was not apparent with DB1 (sense). A random control
sequence with no stable secondary structure ($G = 1.4$ kcal/mol) and unstable

-18-

homodimerisation was also used, called CV3. An additional control applying equal concentration mixture of DB1 and DB1 (sense) gave background levels of defects.

Monitoring of protein knockdown

5 Immunohistochemical localisation of a1 connexin gap junction protein at cell-cell interfaces provides a direct measurement of the anti-sense effect. Anti-peptide a1 connexin specific antibody probes were used to stain wholemount embryos and the connexin distribution was analysed using confocal laser scanning microscopy according to established procedures (Green *et al.*, 1995). Control 10 labelling for two other connexins expressed in the developing chick embryo (connexins b1 & b2) was similarly carried out, also using sequence specific antibodies (Becker *et al.*, 1995).

RESULTS

15

Reduction of a1 connexin expression

Using Pluronic F-127 gel to deliver unmodified a1 connexin specific anti-sense ODN's to the developing chick embryo, protein expression can be interfered with at chosen time points and allows the anti-sense treatment to be targeted to 20 specific regions of a chick embryo. A droplet of gel containing the anti-sense at a relatively low concentration was placed precisely onto individual embryos. The gel sets and remains in place for at least 12 hours and thus a sustained low dose of anti-sense is maintained in this region. The anti-sense applications were targeted and timed to block junction formation prior to the periods of elevated expression in the 25 limb, neural tube and face. These times were chosen to optimise the effects of the anti-sense by reducing the expression of new protein rather than being dependent upon the turnover of protein already in the membranes of the cells of the target tissue. Both DB1 and CG1 ODN's reduced expression of a1 connexin protein within two hours in the neural tube and limb bud, dramatic within 4-8 hours and persisted at 30 18-24 hours and 48 hours in some tissues (data not shown). No down regulation of

-19-

a1 connexin protein was evident in any of the controls used. Equally, two other members of the connexin family expressed in the chick embryo, b1 connexin and b2 connexin, were unaffected by the a1 connexin specific anti-sense ODN.

Several parallel controls were run with all of the experiments. These 5 included; DB1 sense, DB1 anti-sense and DB1 sense combined, DB1 chick (which forms stem loop structures with itself), random ODN's CV3, Pluronic gel alone, Pluronic gel with DMSO and PBS alone). None of the controls had a noticeable effect on a1 connexin protein expression.

10 EXPERIMENT 2

INTRODUCTION

Astrocytes constitute the most abundant cell type in the mammalian brain. They are extensively coupled to one another and to neurons through gap junctions 15 composed predominantly of connexin 43 (Giaume and McCarthy (1996)). Following ischaemia induced or physical brain damage these channels remain open and a spreading wave of depression (initiated by raised interstitial potassium and glutamate and apoptotic signals) is propagated (Cotrina *et al.*, (1998); Lin *et al* (1998)). Waves of increased cytosolic calcium and second messenger molecules such as IP3 are 20 slowly spread via the gap junction channels to neurons beyond the core of the damaged region, resulting in lesion spread in the 24-48 hours following the insult. In this manner, undamaged neighbouring cells are destroyed (Lin *et al.*, 1998), the so-called bystander effect.

This experiment investigates the ability of the formulations of the invention 25 to prevent this bystander effect.

-20-

MATERIALS

Oligodeoxynucleotides were prepared with the following sequences:

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC (connexin 43)

5 TTG TGA TTT ATT TAG TTC GTC TGA TTT C (random control)

METHODS

Oligodeoxynucleotides (ODN's)

10 Unmodified ODN's were delivered in Pluronic F-127 gel (BASF) in phosphate buffered saline (PBS). Pluronic gel is liquid at low temperatures (0-4°C) and sets at physiological temperatures, and is also a mild surfactant. Unmodified ODN's normally have a half life of approximately 20 min in cells (Wagner, 1994) but the Pluronic gel loading method provides a continual diffusion source, the gel acting 15 as a reservoir Becker *et al.*, (1999)). ODN's specific to connexin 43 were applied, or control random ODN's of similar base composition, at 2mM final concentration. Gel only controls were also carried out. ODN's were 30 mers analysed to show that no hairpin looping or homodimerisation should occur.

20 Lesioning

Brain lesions were carried out on 250-300 g male Wistar rats. Animals were anaesthetised with 1-2% halothane in oxygen and the head held in a stereotaxic clamp. The region around the lesion site was shaved and the skin over the skull slit in a sagittal plane with a scalpel and pulled back to leave the skull plates clear. A 0.5 25 mm diameter hole was drilled through the skull plate 3 mm to the right of bregma using an Arlec engraver and a lesion made into the cortex of the brain using a 19G 1½ gauge syringe needle attached to a micrometer stage. The stage allowed accurate directional control and a precise 2 mm penetration depth which kept the lesion within the cortex and well above the corpus callosum.

30 With the animal prepared, 10ml of ice cold Pluronic F-127 gel (BASF)

-21-

containing connexin 43 specific ODN (or a control ODN) was sucked into a precooled 19 G 1½ gauge syringe needle filed off so as to have a flat tip. The syringe needle was attached to a volumetric pipette via a cut down yellow pipette tip. The gel then set in the needle as it warmed to room temperature. The needle with the 5 gel plug at its tip was transferred to a 1 ml syringe containing PBS and a sleeve slipped over the needle shaft so that the needle tip could be lowered into the lesion with the sleeve (coming up against the skull) preventing overpenetration. Gentle pressure on the syringe plunger "popped" the gel plug out of the needle into the lesion. The wound was then treated with hydrogen peroxide to stop bleeding and the 10 skin sutured back into place. Animals were carefully monitored and left until ready for sacrifice 24 hours, 48 hours or 12 days later.

Frozen Sectioning

Animals were sacrificed using Nembutal (pentobarbitone sodium, Virbac) 15 and decapitated. The brains were removed intact and immediately frozen in dry ice snow and stored at -80°C until ready for sectioning. Serial cryosections (30 mm sections) were taken from front to rear (coronal plane), the sections dry mounted onto chrome alum treated slides, and stored for histochemistry or immunohistochemistry at -80°C. The first and last section of each lesion was recorded so that the mid-point 20 sections of the lesion were clearly identified.

Histochemistry

For haematoxylin and eosin staining sections were hydrated through a descending series of alcohols (absolute, 2 x 95%, 1 x 70% and water) and stained in 25 Gill's haematoxylin for 4 minutes. The sections were then washed in water, dipped in Scott's water and rewashed in water. They were then stained for 30 seconds in Moore's buffered eosin. The sections were washed once more in water before dehydration through a series of alcohols (2 x 95%, 1 x absolute), 50:50 alcohol:xylol and dipped in xylene. The sections were then mounted using Histomountä mounting 30 medium.

-22-

For Nissl staining, sections were dehydrated in an ascending graded series of alcohols (75%, 95%, 3 x 100%), five minutes in each, and defatted in xylene for five minutes. The sections were then rehydrated by descending through the same series of alcohols and washed in water. The sections were then placed in a Nissl staining solution (5 ml of a 2% aqueous Cresyl violet stock solution, 90 ml of a 6% glacial acetic acid in water solution, 10 ml of a 1.35% sodium acetate solution) for 10 minutes. The sections were then quickly dehydrated in a series of ascending alcohols for 5 minutes at 75%, then 2 minutes each at 95% and 3 x 100%, three charges of xylene for 10 minutes each. They were then coverslipped with Histomountä

5 mounting medium.

10

Immunohistochemistry

Frozen sections were first allowed to come back up to room temperature in PBS. They were then permeabilised in methanol for two minutes, rinsed in PBS and 15 transferred to a solution of 0.1M lysine and 0.1% Triton-X 100 in PBS for blocking over 30 min. Two washes in PBS, each of two minutes, followed. PBS was removed and 50 ml per section of primary antibody was applied.

20 Immunohistochemistry was carried out with primary antibodies against connexin 43, Neuronal-Nuclei (vertebrate specific nuclear protein NeuN) and GFAP (glial fibrillary acidic protein). The following antibodies were used:

Rabbit anti-Cx 43 (Gourdie *et al.*, (1991)) at a concentration of 1:300.
Mouse anti-Cx 43 (Chemicon International, Inc.) at a concentration of 1:100.
Rabbit anti-rat GFAP (DAKO, Z0334), at a concentration of 1:1000.
25 Mouse anti-Neuronal Nuclei (Chemicon International, Inc.) at a concentration 1:1000.

For connexin and GFAP labelling sections were incubated overnight at 4°C. They were then washed three times 15 minutes in PBS on an orbital shaker.
30 Following this, excess PBS was removed and 50 ml per section of Alexaä 488 anti-

-23-

rabbit IgG (Molecular Probes, Oregon, USA) was applied at a concentration of 1:200. For monoclonals and double labelling a CY3 (Chemicon, 132C) anti-mouse secondary antibody was used. Sections were incubated in the dark for two hours at room temperature followed by three washes of 15 minutes in PBS. For mounting 5 excess PBS was removed from the slides and one or two drops of Citifluor (glycerol/PBS solution) anti-fade medium was applied. A coverslip was lowered onto the sections and sealed with nail varnish. For Neuronal-N labelling the secondary antibody was a biotinylated Goat anti-mouse followed by an avidin linked HRP and DAB reaction (Sigma ExtrAvidin or DAKO Quickstain kit).

10

Imaging and Analysis

Immunofluorescent labelling was carried out using a Leica TCS 4D confocal laser scanning microscope. Double labelled images were subsequently combined using the Leica Combine function or in Adobe Photoshop. Haematoxylin 15 and eosin, and Nissl stained samples or Neuronal-N labelled sections were captured using a Kontron (Zeiss) Progress 3008 digital camera and lesion areas analysed using MetaMorph (Universal Imaging Corp). Lesion areas were analysed for the middle section of each lesion.

20 RESULTS

The well documented spread of brain lesions in the first 24 -48 hours after trauma occurred in our control gel experiments and all lesions, controls and antisense treated, tended to spread near the outer edge where the gel is less likely to sit after loading. However, control lesions spread downwards into the corpus callosum and 25 sideways to form ragged, spreading edges (Figures 1 and 2). Examination of Neuronal-N antibody labelled tissues reveals neuronal death occurring well back from the lesion edge, with areas of Nissl staining in which no viable neurons remain. This spread occurs predominantly within 24 hours (Figures 1 and 2), continuing up to 48 hours after lesioning. This is especially apparent in Figure 2 where neuronal 30 death is evident within 24 hours well back from the lesion edge into otherwise

-24-

normal looking tissue, and the lesion has spread right down into the corpus callosum. In contrast, the better connexin 43 antisense treated lesions remain confined to the original lesion site and have clearly defined base levels (Figures 3 and 4). Neuronal-N labelling colocalises with Nissl stained tissue and none of the connexin 43 antisense treated lesions spread through the corpus callosum. Neuronal-N labelling shows neuronal survival right up to the edge of the original needle tract lesion. Surviving neurons around these lesions often define sharp boundaries marking the edge of the needle tract (Figures 3 and 5). More tissue remains viable within the lesion itself after antisense treatment; in control lesions cell death leads to tissue loss within the lesion area (compare control lesion in Figure 2 at 24 hours with antisense treated lesions in Figures 3 and 4 at 48 hours).

While antibody labelling of glial fibrillary acidic protein (GFAP) shows some increased astrocyte activation at the edges of lesions, connexin 43 protein levels are clearly reduced at many places along the edge of antisense treated lesions, particularly the basal and medial edges (Figure 6) compared with controls (Figure 7). In some areas the only connexin 43 labelling remaining 24 hours after connexin 43 specific antisense treatment is in blood vessel walls despite raised GFAP levels (Figure 6). In general, connexin 43 labelling around antisense treated lesion colocalises to a much lesser extent with GFAP labelling than in controls in which over half of the connexin 43 labelling is astrocyte related. Other connexin levels (connexins 26 and 32) did not appear to be altered by the connexin 43 specific antisense treatments.

36 animals were lesioned. Cross sectional area (central slice of the lesion volume in a coronal plane) was analysed for 21 animals. The results are shown in Table 2.

Table 2

Cross sectional areas of lesions treated with control and connexin 43 specific oligodeoxynucleotides, left empty, or treated with gel only. Measurements are for animals measured after 24 hours, 48 hours and 12 days. Two sets of figures are included - measurements of the entire lesion, and measurements from 1 mm below the surface. In analysis of the second group the largest DB1 treated lesion (brackets) is excluded as it falls outside 3 standard deviations from the mean for this group. Note that the rat brain does heal (unlike other species) and 12 days lesion measurements do not represent the original extend of lesion spread.

DB1 is anti connexin 43 treated

HB3 is random oligo and appears to be toxic

Entire Lesion: (measurements in square mm)

	<i>24 hours</i>	<i>48 hours</i>	<i>12 days</i>
DB1	2.42; 3.16; 3.78; 5.57	3.7; 6.05; 2.91; 3.41; 4.53	2.79; 2.86
HB3	7.14	13.19	
Gel/empty	5.04; 4.48	3.96; 3.41; 3.56; 5.91	2.58; 3.3

Lesions from 1 mm down: (this is considered a more accurate measure as all lesions tend to spread at the outer lip indicating that the treatment gel has settled in the bottom of the lesion and/or the outer cortex has been damaged when drilling the skull or inserting the gel loading needle).

	<i>24 hours</i>	<i>48 hours</i>	<i>12 days</i>
DB1	0.91; 1.13; 2.12; 2.41	(3.38); 0.99; 1.54; 1.44; 1.08	0.47; 1.2
HB3	5.9	5.6	
Gel/empty	3.2; 2.19	1.86; 1.5; 1.68; 2.17	1.07; 1.43

In the final analysis the lesion area from a line 1 mm below the outer cortex edge was measured so as to exclude lesion spread at the outer edge where antisense treatments have little or no effect (owing to gel being injected into and settling at the bottom of lesions). One antisense treated animal falls more than three standard

deviations outside the mean for this group and has been excluded. Mean lesion size for antisense treated lesions at 24 and 48 hours was 1.45 mm^2 (± 0.55), for controls 2.1 mm^2 (± 0.6). The four smallest (of 8 antisense treated and 8 control lesions at 24 and 48 hours) were all connexin 43 antisense treated, with the smallest control lesion 50% larger than these four. This data is also shown in graphical form in Figure 8. By 12 days regeneration occurs in the rat (but not in human brain tissue)

and the limits of lesion spread are not clearly defined.

DISCUSSION

The Pluronic gel plug - antisense ODN method has been used to study the
5 effect of connexin 43 knockdown during astrocytosis which occurs following
lesioning of the cerebral cortex of the mammalian brain. In the brain, release of
toxins from dying neurons causes what is known as the bystander effect, with the
toxins spreading to neighbouring cells through gap junction channels (Lin *et al*,
(1998)). Under neurodegenerative conditions, slow release of toxins apparently leads
10 to an upregulation of connexin 43 channels in astrocytes to enable the transport and
removal of the toxins to the blood stream. In cases of severe trauma however, this
upregulation aids the spread of high toxin levels to neighbouring neurons, killing
them. Blocking of the connexin 43 upregulation and knockdown of connexin 43
channels prevents this spread leading to lesions up to 50% smaller in cross sectional
15 area. This has significant implications in the management of ischaemic stroke,
treatment of neurodegenerative diseases, and modulation of side effects from surgical
intervention.

EXPERIMENT 3

20

INTRODUCTION

The bystander effect in neural tissues whereby damaged neurons release
toxins which spread and kill neighbouring cells is well documented. Experiment 2
shows that this effect can be reduced in the brain using an antisense
25 oligodeoxynucleotide sustained release approach to knockdown the gap junction
protein connexin 43.

Another tissue of similar composition to the brain is the spinal cord in which
the neural population is supported by populations of glial cells, including astrocytes
which are responsible for the neuroprotective effect by removing glutamate and
30 excess calcium from the neural environment. This experiment investigates the ability

-27-

of the formulations of the invention to reduce the spread of spinal cord lesions.

MATERIALS

Oligodeoxynucleotides were prepared with the following sequences:

5

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC (connexin 43)

GAC AGA AAC AAT TCC TCC TGC CGC AAT TAC (sense control)

METHODS

10 Wistar rats were anaesthetised and their spinal cord exposed. A standard hemisection lesion was then made in the cord and 5 ml of chilled Pluronic gel, containing either antisense or sense ODN's to connexin 43 (5mM) was placed in the lesion. Applications were made blind. The exposed cord was then recovered and the rat returned to its cage. Some animals were sacrificed at 24 hours whereas others
15 were maintained for 12 days and two months in order to determine the extent of neuronal regeneration and the final size of the lesion. For axonal regeneration studies the rats were anaesthetised and their axons severed prior to their entry site to the spinal cord. A pellet of Horse radish peroxidase (HRP) was placed in the cut in order to retrogradely label the axons over a 24 hour period. Next day the rats were
20 sacrificed and their spinal cords removed and fixed in 2% paraformaldehyde. Cords were then processed for cryosectioning and serial longitudinal 8 mm sections were taken through the cords. Sections were then immunostained for either connexins or GFAP along with propidium iodide as a nuclear marker, or processed to reveal the HRP.

25

RESULTS

At 24 hours post lesion there was a marked difference between the spinal cord lesions treated with connexin 43 sense and antisense ODN's. The sense lesions appeared no different from untreated controls whereas the antisense treated lesions
30 appeared smaller and less inflamed (Figure 9).

-28-

At 12 days HRP labelled axons could be seen in both sense and antisense treated cords but in neither case did significant numbers of regenerating axons cross the lesion. However, there was a marked difference in lesion size with the antisense lesion appearing significantly smaller than the sense or untreated lesions.

5 Two months after lesioning the spinal cords HRP labelling of regenerating axons revealed that they had failed to cross the lesion site in both sense and antisense treatments. Lesion size was significantly smaller in antisense treated cords indicating a significant reduction in secondary neuronal cell death.

10 DISCUSSION

Using the formulations of the invention, the antisense oligodeoxynucleotide knockdown of connexin 43 significantly reduces the lesion spread which occurs in the first 24-48 hours after spinal cord injury. The knockdown of connexin 43 also reduces inflammation, further aiding in the neuroprotective effect, but there was no 15 change in the ability for neurons to grow back across the lesion site. Thus, antisense treatment with connexin 43 specific oligodeoxynucleotides cannot aid regrowth of damaged neurons, but has a significant neuroprotective effect reducing the spread of the insult.

20 EXPERIMENT 4

INTRODUCTION

To repair skin wounds a number of cell types, such as fibroblasts, endothelial cells and keratinocytes are activated to proliferate, migrate and lay down 25 extracellular matrix to fill the wound.

Communication and intercellular signalling is a key feature of the wound healing process. Extracellular signalling mechanisms are thought to be the key players though it is also probable that intercellular signalling through the extensive networks of gap junction channels in the skin layers may also have a role. Calcium 30 waves spreading away from injured cells through the epidermis may signal their

-29-

damage. In normal wound healing connexin levels start to fall within 6 hours and take up to 6 days to recover. The roles that these changes play are not understood but one theory is that cells are released from their neighbours to divide rapidly, and then junctions reform to coordinate migration into and over the wound site.

5 This experiment investigates the ability of the formulations of the invention to effect wound healing.

MATERIALS

Oligodeoxynucleotides were prepared with the following sequences:

10
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC (connexin 43)
GAC AGA AAC AAT TCC TCC TGC CGC AAT TAC (sense control)

METHODS

15 Neonatal mice, CD1 strain, were anaesthetised with local anaesthetic by spray. A clean incision wound, 2 mm long, was then made along the length of both fore paws with an iridectomy knife. By making the wounds under a dissecting microscope they can be made very reproducible in size. They generally heal in 3-6 days. Carbon powder was dusted into the wounds in order to mark them for
20 subsequent identification of the wound site at late time points - this does not affect the healing in any way. 5 ml of chilled Pluronic gel, containing either Sense or Antisense ODN's was then applied to the wounds. The Pluronic gel is liquid between 0-4°C but sets at higher temperature. Once applied to the wound the gel sets in place and acts as a slow release reservoir for the ODN's as well as a mild
25 surfactant, aiding the penetration of ODN's into the tissue. Application of Sense ODN's was made to one paw and Antisense to the other, alternating left and right between litters. Pups were warmed under a lamp and then returned to their mother. Wounds were examined daily and scored for quality of healing. Representative pups were selected at 1 day, 5 day and 8 day post operation and their forelimbs
30 photographed before the pups were anaesthetised and perfused with 2%

-30-

paraformaldehyde. The forelimbs were removed and immersion-fixed in 2% paraformaldehyde overnight and then processed for resin (1 day) or wax (2 days onward) histology.

5 **Inflammation** of the wound was assessed 24 hours after wounding. Resin sections through the wound are stained with Toluidine blue to reveal nissl positive cells, neutrophils, which are the first cells to respond to injury. These can also be revealed using neutrophil specific markers.

10 **Cell death** and clearance is assessed by Tunel labelling to determine the rate of clearance of apoptotic cells. Macrophage staining was used to show the period of clearing up following cell death. These are carried out days 3-5 post wounding.

Angiogenesis

15 Granulation is a feature of healing connective tissue and is cased by the invasion of numerous capillaries. Macrophages are known to express potent angiogenic factors such as VEGF. The degree of vascularisation is monitored with antibodies to VEGF receptors, anti-PCAM and anti-flt-1 which are both good blood vessel markers. Contraction of this tissue is brought about by the differentiation of wound fibroblasts into a contractile myofibroblast. After they have pulled the wound together they die apoptotically and are removed by macrophages. These cells can be 20 revealed by smooth muscle actin specific antibodies and their formation and removal followed.

Hyperinnervation

25 Sensory nerves are very sensitive to the signals released on wounding and show transient sprouting at the sites of adult wounds. However, in neonatal wounds this sprouting is more profuse and results in permanent hyperinnervation. Whilst it is not clear what these signals are it is likely that they are released from inflammatory macrophages. Hyperinnervation is maximal at 7d post wounding and nerve distribution can be revealed using PGP 9.5 antibody against neurofilaments.

30 **Scarring** is normally assessed weeks or months after closure of the wound.

-31-

However, a reasonable assessment can be made 12 days after wounding. Sections through the wounds are stained with the collagen stain Picosirus Red and examined on a confocal microscope to determine the collagen density and orientation at the wound site.

5

RESULTS

1 day

At 24 hours after wounding marked differences were apparent between the 10 sense and antisense treated limbs. Sense treated wounds looked no different from untreated with a normal spectrum of healing grades and rates (Figure 10). Antisense treated limbs were markedly different from the controls, they appeared to be less inflamed and the healing rate was generally faster.

Resin sections of representative limbs stained with a nissl stain revealed 15 significantly less neutrophils cells indicating a less inflamed tissue (Figure 11).

5 days

By days after wounding scabs had started to fall off. At this stage most of the antisense treated wounds appeared to be smaller than the sense treated with either 20 small scabs or less prominent scarring (Figure 12).

8 days

8 days after wounding the limbs had grown hair. Sense treated wounds were still visible being demarcated by a lack of hair around the wound site.

25 Antisense treated wounds were mostly invisible being covered by normal hair growth. This difference in hair growth indicates reduced scarring has occurred in the antisense treated wounds (Figure 13).

-32-

CONCLUSIONS

Application of connexin 43 antisense ODN's to a wound has a marked affect on the healing process. The first noticeable effect is a reduction in the inflammation of the wounds which is noticeable in sections which show a much 5 lower inflammatory response in terms of levels of neutrophils. As healing progresses, antisense treated wounds heal faster and with less scarring than control lesions.

This reduction in inflammatory response and subsequent improved healing is possibly owing to reduced neutrophil communication and to a speeding up of 10 natural healing processes. The antisense ODN's can reduce connexin expression in 4-8 hours so they will not have an effect on the initial signalling of wounding but play a role in the secondary signalling events. It is interesting to note that neutrophils which invade in response to the wounding normally express large amounts of 15 connexin 43. It is also possible that they form gap junctions with other cells in the wound and communicate with them. Reduction in this form of communication may result in a reduction of secreted factors from the neutrophils and may reduce cell death in the wound as well as granulation and hyperinnervation. It is also known that under normal conditions connexin protein levels (connexins 26, 31.1 and 43) are reduced in both the epithelial and subdermal layers of wounds starting within 6 20 hours, and remaining lowered for up to 6 days. The antisense approach may speed up this initial protein reduction by blocking translational processes as protein removal from the membrane is occurring. Certainly, the effects of connexin 43 knockdown immediately following wounding has marked effects on reducing inflammatory levels and increasing healing rates.

25

EXPERIMENT 5

INTRODUCTION

The inflammation and secondary cell death that follows burning is of major 30 concern. Victims of severe burns over a high percentage of their body often die one

-33-

or two days after trauma. This experiment investigates the ability of the formulations of the invention to beneficially affect the burn recovery process.

MATERIALS

5 Oligodeoxynucleotides were prepared with the following sequences:

GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC (connexin 43)

GAC AGA AAC AAT TCC TCC TGC CGC AAT TAC (sense control)

10 METHODS

Reproducible burns are delivered to moistened skin, and Pluronic gel containing antisense ODN's injected subdermal to the burn. A series of burns were made using a soldering iron to the left and right sides of the skull of six newborn mice. The burns on one side of the head were treated with connexin 43-specific

15 ODN in Pluronic gel and those on the other side with sense control ODN in Pluronic gel.

RESULTS

After 24 hours, all six connexin 43 ODN treated burns showed lower levels
20 of inflammation compared with the control burns. These differences were marked
(data not shown).

UTILITY

Thus, in accordance with the invention, there are provided formulations by
25 which cell-cell communication can be downregulated in a transient and site-specific manner. The formulations therefore have application in methods of therapy and in cosmetic treatments.

The delivery of the ODN component of the formulation for an extended period (24 hours or longer) is a particular advantage in treating neuronal damage.
30 This is because, in most instances of direct physical neuronal insult, neuronal cell

loss extends well beyond the site of actual injury to the surrounding cells. This secondary neuronal cell loss occurs within 24 hours of the original injury and is mediated by junction gap cell-cell communication. Downregulation of connexin protein expression therefore blocks or at least downregulates communication between the cells and minimises secondary neuronal cell damage.

Equally, in instances of other tissue damage (particularly wounds) the formulations of the invention have been found effective in both promoting the wound healing process, reducing inflammation and in minimising scar formation. The formulations therefore have clear benefit in the treatment of wounds, whether the result of external trauma (including burns) or surgical intervention.

It will further be appreciated that the above description is provided by way of example only and that modifications can be made, both in terms of the specific ODN's and pharmaceutically acceptable carriers or vehicles employed without departing from the scope of the present invention.

15

Table 1

1	atgggtgact ggagcgcc tt aggcaaactc cttgacaagg ttcaaggccta ctcaactgct
61	ggagggaaagg tttggctgtc agtacttttc attttccgaa tcctgctgtc ggggacagcg
121	gttgagtca gctggggaga tgaggcgtct gccttcgtt gtaacactca gcaaccctgtt
181	tgtgaaaatg tctgctatga caagtc ttcc ccaatcttc atgtcgctt ctgggtcctg
241	cagatcatat ttgtgtctgt acccacactc ttgtacccctgg ctcatgtgtt ctatgtgtat
301	cgaaaggaag agaaactgaa caagaaagag gaagaactca aggttgccca aactgtatgg
361	gtcaatgtgg acatgcattt gaagcagatt gagataaaga agttcaagta cggattgtaa
421	gagcatggta aggtgaaaat gcgggggggg ttgctgcgaa cctacatcat cagtatcc
481	tcaagtcata tccttgagggt ggccttc tt ctgatccagt ggtacatcta tggattcagc
541	ttgagtgtctg ttacacttgc caaaagagat ccctgccc acatagggtggc ctgttcc
601	tctcgccccca cggagaaaac catcttcattt atcttcatttgc ttgggtgtc ttgggtgtcc
661	ctggccttga atatcatttgc actcttcattt gttttctca agggcgtaa ggatcggtt
721	aaggaaaga gcgacccttta ccatgcgacc agtggtgcc tgagccctgc caaagactgt
781	gggtctaaa aatatgcata ttcaatggc tgctccatca caaccgc tccctcgcc
841	atgttcctc ctgggttacaa gctgggtact ggcgacagaa acaatttc ttggccaaat
901	tacaacaaggc aagcaagtga gcaaaactgg gctaatttaca gtgcagaaca aaatcgat
961	gggcaggcgg gaagcaccat ctctactcc catgcacagc cttttgattt ccccgatgt
1021	aaccagaattt ctaaaaaactt agctgtggc catgaatttac agccacttagc catttgcgt
1081	cagcgaccctt caagcagac cagcagtcgt ggcagcagca gacctcgcc tggatgcac
1141	gagatctag

-35-

REFERENCES

Becker, D. L., Evans, W. H., Green, C. R., Warner, A. (1995): Functional analysis of amino acid sequences in connexin 43 involved in intercellular communication
5 through gap junctions. *J. Cell Sci.* **108**, 1455-1467.

Becker, D. L., McGonnell, I., Makarenkova, H. P., Patel, K., Tickle, C., Lorimer, J. and Green, C. R. (1999). Roles for a1 connexin in morphogenesis of chick embryos revealed using a novel antisense approach. *Devel. Genetics*, **24**, 33-42.
10

Cotrina, M. L., Kang, J., Lin, J. H-C., Bueno, E., Hansen, T. W., He, L., Lie, Y. and Nedergaard, M. (1998). Astrocytic gap junctions remain open during ischemic conditions. *J. Neurosci.*, **18**, 2520-2537.

15 Giaume, C. and McCarthy, K. D. (1996). Control of gap-junctional communication in astrocytic networks. *TINS*, **19**, 319-325.

Gourdie, R. G., Green, C. R., Severs, N. J. (1991). Gap junction distribution in adult mammalian myocardium revealed by an anti-peptide antibody and laser scanning
20 confocal microscopy. *J. Cell Sci.* **99**: 41-55.

Green, C. R., Bowles, L., Crawley, A., Tickle C. (1994): Expression of the connexin 43 gap junctional protein in tissues at the tip of the chick limb bud is related to epithelial-mesenchymal interactions that mediate morphogenesis. *Devel. Biol.*, **161**, 12-21.
25

Lin, J. H., Weigel, H., Cotrina, M. L., Liu, S., Bueno, E., Hansen, A. J., Hansen, T. W., Goldman, S. and Nedergaard, M. (1998). Gap-junction-mediated propagation and amplification of cell injury. *Nature Neurosci.*, **1**, 431-432.
30

-36-

Neckers, L., Whitesell, L. (1993): Anti-sense technology: biological utility and practical considerations. *Am. J. Physiol.* 265 (lung cell mol physiol), L1-L12.

Simons, M., Edelman, E. R., DeKeyser, J. L., Langer, R., Rosenberg, R. D. (1992):

5 Anti-sense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation *in vivo*. *Nature*, 359, 67-70.

Stein, C. A. (1992): Anti-sense oligodeoxynucleotides - promises and pitfalls, *Leukemia* 6, 967-974.

10

Wagner, R. W. (1994): Gene inhibition using anti-sense oligodeoxynucleotides, *Nature*, 372, 333-335.

CLAIMS

1. A formulation for use in therapeutic and/or cosmetic treatment, which formulation comprises:

5 at least one anti-sense polynucleotide to a connexin protein; together with a pharmaceutically acceptable carrier or vehicle.

2. A formulation according to claim 1, suitable for topical administration.

3. A formulation according to claim 1 or 2, wherein the polynucleotide is 10 an oligodeoxynucleotide.

4. A formulation according to any preceding claim which contains polynucleotides to one connexin protein only.

5. A formulation according to claim 4 wherein said connexin protein is connexin 43, connexin 26, connexin 31.1, connexin 32 or connexin 36.

15 6. A formulation according to any of claims 1 to 3 which contains polynucleotides to more than one connexin protein.

7. A formulation according to claim 6 in which one of the connexin proteins to which polynucleotides are directed is connexin 43.

8. A formulation according to claim 6 which includes polynucleotides 20 directed to at least two of connexin 26, connexin 31.1, connexin 32, connexin 36 and connexin 43.

9. A formulation according to claim 5, claim 7 or claim 8 in which the polynucleotide to connexin 43 is selected from:

25 GTA ATT GCG GCA AGA AGA ATT GTT TCT GTC;
GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC; and
GGC AAG AGA CAC CAA AGA CAC TAC CAG CAT.

30 10. A formulation according to claim 5 or claim 8 in which the polynucleotide to connexin 26 is:

-38-

TCC TGA GCA ATA CCT AAC GAA CAA ATA.

11. A formulation according to claim 5 or claim 8 in which the polynucleotide to connexin 31.1 is:

5

CGT CCG AGC CCA GAA AGA TGA GGT C.

12. A formulation according to claim 5 or claim 8 in which the polynucleotide to connexin 32 is:

10

TTT CTT TTC TAT GTG CTG TTG GTG A.

13. A formulation according to any preceding claim in which the pharmaceutically acceptable carrier or vehicle is, or includes, a gel.

15

14. A formulation according to claim 13 in which the gel is a nonionic polyoxyethylene-polyoxypropylene copolymer gel.

15. A formulation according to any preceding claim which further includes a surfactant or urea to assist with polynucleotide penetration into cells.

16. A method of site-specific downregulation of connexin protein expression for a therapeutic and/or cosmetic purpose which comprises administering a formulation as defined in any one of claims 1 to 15 to a site on or within a patient at which said downregulation is required.

20
25
17. A method of reducing neuronal cell death which would otherwise result from a neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient which comprises the step of administering a formulation as defined in any one of claims 1 to 15 to said site to downregulate expression of connexin protein(s) at and immediately adjacent said site.

30
18. A method according to claim 17 in which the formulation is administered to reduce neuronal loss due to physical trauma to the brain, spinal cord or optic nerve.

19. A method according to claim 17 or claim 18 in which the formulation is administered in a sufficient amount to downregulate expression of said connexin protein(s) for at least 24 hours post-administration.

20. A method of promoting wound healing in a patient which comprises
5 the step of administering a formulation as defined in any of claims 1 to 15 to said wound to downregulate expression of connexin protein(s) at and immediately adjacent the site of said wound.

21. A method according to claim 20 in which the wound is the result of
trauma.

10 22. A method according to claim 21 in which the trauma is a burn.

23. A method according to claim 20 in which the wound is the result of
surgery.

15 24. A method of reducing inflammation as part of treating a wound and/or tissue subjected to physical trauma which comprises the step of administering a formulation as defined in any one of claims 1 to 15 to, or proximate to, said wound or tissue.

25. A method according to claim 24 in which the formulation is administered to reduce inflammation due to physical trauma to the brain, spinal cord or optic nerve.

20 26. A method of decreasing scar formation in a patient who has suffered a wound which comprises the step of administering a formulation as defined in any one of claims 1 to 15 to said wound to downregulate expression of connexin protein(s) at and immediately adjacent the site of said wound.

25 27. A method of skin rejuvenation or thickening for a cosmetic or therapeutic purpose which comprises the step of administering, once or repeatedly, a formulation as defined in any one of claims 1 to 15 to the skin surface.

28. A method according to claim 27 wherein said formulation includes polynucleotide directed to connexin 43 and is administered to regulate epithelial basal cell division and growth.

-40-

29. A method according to claim 27 wherein said formulation includes polynucleotide directed to connexin 31.1 and is administered to regulate outer layer keratinisation.

30. A method according to any one of claims 27 to 29 wherein the 5 formulation is a cream.

31. The use of at least one anti-sense polynucleotide to a connexin protein in the manufacture of a medicament for downregulating expression of said connexin protein for a therapeutic or cosmetic purpose.

32. The use of claim 31 wherein said medicament is for reducing neuronal 10 cell death which would otherwise result from a neuronal insult.

33. The use of claim 31 wherein said medicament is for promoting wound healing.

34. The use of claim 31 wherein said medicament is for reducing inflammation.

15 35. The use of claim 31 wherein said medicament is for decreasing scar formation.


36. The use of claim 31 wherein said medicament is for skin rejuvenation for a cosmetic or therapeutic purpose.

09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 1A



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 1B



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 1C



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 1D



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 2A



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 2B



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 3A



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 3B



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 4A



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 4B




09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 5



09/890363

WO 00/44409

PCT/GB00/00238

FIGURE 6





FIGURE 7

09/890363

WO 00/44400

PCT/GB00/00238

Comparison of lesion areas with different treatments




FIGURE 8

09/890363

WO 00/44409

PCT/GB00/00238




FIGURE 9




FIGURE 10

09/890363

WO 00/44409

PCT/GB00/00238




FIGURE 11

09/890363

WO 00/44409

PCT/GB00/00238




FIGURE 12

09/890363

WO 00/44409

PCT/GB00/00238




FIGURE 13

INVENTOR DECLARATION

Attorney Docket No.
P02246US0

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
FORMULATIONS COMPRISING , the specification of which
ANTISENSE NUCLEOTIDES TO
CONNEXINS is attached hereto.

was filed on as Application Serial No
 (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

			Priority Claimed	
<u>333928</u> (Number)	<u>New Zealand</u> (Country)	<u>27 January 1999</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u>500190</u> (Number)	<u>New Zealand</u> (Country)	<u>07 October 1999</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<u></u> (Number)	<u></u> (Country)	<u></u> (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No



I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:


<u></u> (Application Serial No.)	<u></u> (Filing Date)
<u></u> (Application Serial No.)	<u></u> (Filing Date)

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s), or § 365(b) of any PCT international application designating the United States of America, listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. or PCT international application in the manner provided by the first paragraph of Title 35, U.S.C. §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/GB00/00238</u> (Application Serial No.)	<u>27 January 2000</u> (Filing Date)	<u></u> (Status)
<u></u> (Application Serial No.)	<u></u> (Filing Date)	<u>(patented, pending, abandoned)</u> (Status)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First Inventor <u>David Laurence BECKER</u>	Inventor's Signature 	Date 19-7-01
Residence 19 Lapwing Way, <u>Abbots</u> , Langley, Hertfordshire, United Kingdom	Box	Citizenship 
Post Office Address as above		

Full Name Second Inventor <u>Colin Richard GREEN</u>	Inventor's Signature 	Date 19-7-01
Residence 3/4 Crescent Road, <u>Epsom</u> , Auckland 3, New Zealand	Box	Citizenship 
Post Office Address as above		

Full Name Third Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		

Full Name of Fourth Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		

Full Name of Fifth Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		

Full Name of Sixth Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		

Full Name of Seventh Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		

POWER OF ATTORNEY

UNIVERSITY COLLEGE LONDON, assignee of all right, title and interest in the enclosed patent application, hereby appoints the following agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ronald G. Bliss	Reg. No. 28,691
Paul E. Krieger	Reg. No. 25,886
Robert J. Koch	Reg. No. 26,637
Paul L. Deverter	Reg. No. 19,747
James W. Repass	Reg. No. 30,487
Thomas D. Paul	Reg. No. 32,714
Marc L. Delflache	Reg. No. 28,942
David L. Fox	Reg. No. 40,612
Jan K. Simpson	Reg. No. 33,283
John M. Mings	Reg. No. 35,955
Mark E. Ungerman	Reg. No. 32,070
Peter J. Davis	Reg. No. 36,119
Scott Denko	Reg. No. 37,606
Charles B. Walker, Jr.,	Reg. No. 43,231
Richard S. Zembek	Reg. No. 43,306
Alberto Amatong	Reg. No. 41,580
Gino Catena	Reg. No. 45,546
Melissa Acosta	Reg. No. 45,872
Melissa Schwaller	Reg. No. 46,089
Melissa Sistrunk	Reg. No. 45,579
Michael S. McCoy	Reg. No. P-46,913
Eric Hall	Reg. No. P-46,751

Address all correspondence to Patent Department, Fulbright & Jaworski L.L.P., 1301 McKinney, Suite 5100, Houston, Texas 77010-3095.

UNIVERSITY COLLEGE LONDON

J.D. Skinner
Director
UCL Ventures

DATE: 20-07-01

09/890363

-1-

SEQUENCE LISTING

<110> University College London
Becker, David L
Green, Colin R

<120> Formulations

<130> N78821 TAC

<140> PCT/GB00/00238
<141> 2000-01-27

<150> NZ 333928
<151> 1999-01-27

<150> NZ 500136
<151> 1999-10-07

<160> 12

<170> PatentIn Ver. 2.1

<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 1
gtaattgcgg caagaagaat tgtttctgtc

30

<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

-2-

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 2
gtaattgcgg caggaggaat tgtttctgtc

30

<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 3
ggcaagagac accaaagaca ctaccagcat

30

<210> 4
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 4
tcctgagcaa tacctaacga acaaata

27

<210> 5
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 5
cgtccgagcc cagaaagatg aggtc

25

<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 6
tttctttct attgctgtt ggtga

25

<210> 7
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 7
gacagaaaaca attcctcctg ccgcaattac

30

<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 8
gtatgtttacga caggaggaat ttttttttttgc

30

<210> 9
<211> 30
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 9

tcgaactgtc aagactgcta tggcgatcat

30

<210> 10

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 10

ttgtgattta ttttagttcgt ctgatttc

28

<210> 11

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 11

gacagaaaaca attcctcctg ccgcaattac

30

<210> 12

<211> 1149

<212> DNA


<213> Homo sapiens

<400> 12

atgggtgact ggagcgccctt aggcaaactc cttgacaagg ttcaagccta ctcaactgct 60
ggagggagg tgtggctgtc agtactttc attttcccaa tcctgctgct ggggacagcg 120
gttgagtcag cctggggaga tgagcagtct gccttcgtt gtaacactca gcaacctgg 180

tgtaaaaatg tctgctatga caagtcttc ccaatctctc atgtgcgtt ctgggtcctg 240
cagatcatat ttgtgtctgt acccacactc ttgtacctgg ctcatgtgtt ctatgtatg 300
cgaagaaag agaaactgaa caagaaagag gaagaactca aggttgccta aactgtatg 360
gtcaatgtgg acatgcactt gaagcagatt gagataaaga agtcaagta cggatttggaa 420
gagcatggta aggtgaaaat gcgagggggg ttgctgcgaa cctacatcat cagtatcctc 480
ttcaagtcta tctttgaggt ggccttctt ctgatccagt ggtacatcta tggattcagc 540
ttgagtctg tttacactt caaaagagat ccctgccccac atcaggtgga ctgtttcctc 600
tctcgccccca cggagaaaac catcttcatc atcttcatgc tgggtgtgtc ctgggtgtcc 660
ctggccttga atatcattga actcttctat gtttcttca agggcgttaa ggatcggggtt 720
aaggaaaga ggcgaccctt ccattgcgacc agtgggtgcgc tgagccctgc caaagactgt 780
gggtctcaaa aatatgctt tttcaatggc tgctcctcac caaccgctcc cctctcgccct 840
atgtctcctc ctgggtacaa gctggttact ggcgacagaa acaattctt ctttgcgatgat 900
tacaacaagc aagcaagtga gcaaaaactgg gctaattaca gtgcagaaca aaatcgaatg 960
ggcaggcgg gaagcaccat ctctaactcc catgcacagc ctttgcgatgat ccccgatgat 1020
aaccagaatt ctaaaaaact agctgctgga catgaattac agccacttagc cattgtggac 1080
cagcgcacccctt caagcagagc cagcagtcgt gccagcagca gacccctggcc tggatgacctg 1140
gagatcttag

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

Scanned copy is best available. Drawing figures are dark